Waters Corporation (NYSE:WAT) reported fourth-quarter 2019 non-GAAP earnings of $3.20 per share, which surpassed the Zacks Consensus Estimate by 5.9%. However, the figure improved 11.5% on a year-over-year basis and 50.2% sequentially.
Net sales of $716.3 million beat the Zacks Consensus Estimate of $713.9 million. The top line was up 0.2% from the year-ago quarter on the reported basis and 1% on constant currency basis. Further, the figure improved 24.1% from the prior quarter.
Sluggishness in year-over-year top-line growth can be attributed to softness in pharmaceutical and industrial market. Further, the company encountered weakness in the Americas and Europe regions during the third quarter.
Nevertheless, Waters witnessed solid momentum across Asia and the governmental & academic market during the reported quarter.
Further, the company remains optimistic regarding strengthening growth initiatives and increasing R&D activities aimed at bolstering the new product cycle, which are likely to instill investor optimism in the near term.
Top Line in Detail
Waters’ net sales figure can be categorized in four ways:
By Operating Segment: The company operates in two organized segments — Waters and TA.
Waters segment (88.6% of net sales) generated $634.31 million of sales, up 1.5% from the year-ago quarter. Sales in TA segment came in $81.99 million and accounted for 11.4% of the net sales. The figure reflected year-over-year decline of 8.8%.
By Products & Services: This division comprises three segments — Instruments, Services and Chemistry.
Instruments sales (52.6% of sales) came in $376.6 million, down 3.9% on a year-over-year basis.
Service sales (31.7% of the sales) were $227.4 million, improving 5% year over year.
Chemistry sales (15.7% of the sales) were $112.2 million, advancing 5.4% from the year-ago quarter.
Moreover, service and chemistry sections together generated recurring revenues of $339.7 million, up 5% from the year-ago quarter.
By Markets: The company serves three end markets — Pharmaceutical, Industrial and Governmental & Academic.
Pharmaceutical market (54.8% of net sales) generated sales of $392.4 million, down 1% on a year-over-year basis.
Industrial market (30.3% of sales) sales came in $216.7 million, down 1% from the year-ago quarter.
Governmental & Academic (14.9% of sales) generated $107.2 million of sales. The figure improved 8% year over year.
By Geography: This company’s operating regions include Asia, Americas and Europe.
Asia (36.6% of net sales) generated $261.9 million of sales, down 0.3% on a year-over-year basis.
Americas (34.2% of sales) generated $245.1 million of sales, decreasing 1% year over year.
Europe (29.2% of sales) generated $209.2 million of sales, up 3% from prior-year quarter.
Operating Details
In the fourth quarter, non-GAAP selling and administrative expenses were $139.4 million, suggesting a decline of 2.6% from the year-ago quarter.
Per management, research and development spending was $37.1 million, indicating a decline of 2.7% form the year-ago reported figure.
Adjusted operating margin was 33.6%, which contracted 90 bps year over year.
Balance Sheet & Cash Flow
As of Dec 31, 2019, cash, cash equivalents and investments came in $337.1 million, lower than $404.65 million as of Sep 28, 2019.
Further, total liabilities were $2.8 billion, up from $2.4 billion in the prior quarter.
Waters generated cash from operation of $191.9 million in the fourth quarter, up from $148.4 million in the previous quarter.
Further, free cash flow of $157.6 million in the reported quarter.
Guidance
For first-quarter 2020, Waters expects non-GAAP earnings in the range of $1.55-$1.65 per share. The Zacks Consensus Estimate for earnings is pegged at $1.87 per share.
The company anticipates net sales growth between 0% and 2% on a constant currency basis. The Zacks Consensus Estimate for sales is currently projected at $533.53 million.
For 2020, Waters expects non-GAAP earnings in the range of $9.15-$9.40 per share. The Zacks Consensus Estimate for 2019 earnings is pegged at $9.86 per share.
Further, the company’s net sales growth on a year-over-year basis is anticipated between 1% and 3 on a constant currency basis. The Zacks Consensus Estimate for sales is pegged at $2.50 billion.
Zacks Rank & Other Key Picks
Waters currently has a Zacks Rank #2 (Buy).
Splunk (NASDAQ:SPLK) , Garmin (NASDAQ:GRMN) and Benefitfocus (NASDAQ:BNFT) are some better-ranked stocks in the broader computer and technology sector. All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Splunk, Garmin and Benefitfocus is pegged at 31.24%, 7.35% and 25%, respectively.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year. So be sure to give these hand-picked 7 your immediate attention.
See 7 handpicked stocks now >>
Benefitfocus, Inc. (BNFT): Free Stock Analysis Report
Splunk Inc. (SPLK): Free Stock Analysis Report
Garmin Ltd. (GRMN): Free Stock Analysis Report
Waters Corporation (WAT): Free Stock Analysis Report
Original post
Zacks Investment Research